About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Aurobindo Pharma Ltd.
Change Company
BSE Code
524804
ISIN Demat
INE406A01037
Book Value
353.55
NSE Code
AUROPHARMA
Dividend Yield %
0.00
Market Cap
691502.41
P/E
39.59
EPS
30.08
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
03-Jul-2025
Aurobindo Pharma’s arm obtains marketing authoriz...
03-Jul-2025
Aurobindo Pharma informs about compliance certifi...
30-Jun-2025
Aurobindo Pharma’s arm restarts Penicillin-G manu...
30-Jun-2025
Aurobindo Pharma moves up as its arm restarts Pen...
25-Jun-2025
Aurobindo Pharma’s arm obtains marketing authoriz...
25-Jun-2025
Aurobindo Pharma surges as its arm obtains market...
20-Jun-2025
Aurobindo Pharma submits analyst meet intimation
16-Jun-2025
Aurobindo Pharma’s arm incorporates wholly owned ...
29-May-2025
Aurobindo Pharma inches up as its arm incorporate...
28-May-2025
Aurobindo Pharma’s arm incorporates wholly owned ...
14-May-2025
Aurobindo Pharma’s arm obtains marketing authoris...
26-Apr-2025
Aurobindo Pharma informs about press release
24-Apr-2025
Aurobindo Pharma trades green on the BSE
23-Apr-2025
Aurobindo Pharma’s arm gets USFDA's nod to manufa...
23-Apr-2025
Aurobindo Pharma soars as its arm gets USFDA's no...
Page
1
of
4
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.